BRIEF-Civeo To Acquire Four Villages In Australian Bowen Basin-March 2024-www.financetom.com

BRIEF-Civeo To Acquire Four Villages In Australian Bowen Basin

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-Civeo To Acquire Four Villages In Australian Bowen Basin

Feb 19, 2025 3:52 AM

Feb 19 (Reuters) - Civeo Corp ( CVEO ):

* CIVEO TO ACQUIRE FOUR VILLAGES IN AUSTRALIAN BOWEN BASIN

* CIVEO CORP ( CVEO ) - DEAL VALUED AT A$105 MILLION, OR

APPROXIMATELY

US$67 MILLION

* CIVEO CORP ( CVEO ) - EXPECTED ANNUALIZED REVENUE OF A$50 MILLION

AND

EBITDA OF A$27 MILLION

Source text:

Further company coverage:

Previous page： NIO Completes $1.16 Billion Public Offering Next page： African manufacturers in last-ditch bid to extend US trade programme

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

NIO Completes $1.16 Billion Public Offering

Sep 17, 2025

06:22 AM EDT, 09/17/2025 (MT Newswires) -- NIO (NIO) said Wednesday that it completed a $1.16 billion offering of 209.1 million shares, consisting of 160.8 million American depositary shares, 21.0 million ordinary shares, and 27.3 million American depositary shares by the underwriters' full exercise of their option. The depositary shares were sold for $5.57 each, while the ordinary shares were...

African manufacturers in last-ditch bid to extend US trade programme

Sep 17, 2025

NAIROBI (Reuters) - African manufacturers are lobbying U.S. Congress to grant a last-ditch extension of one or two years to a duty-free trade programme due to expire at the end of September, a Kenyan factory owner involved in the campaign told Reuters. U.S. President Donald Trump's aggressive tariff policies have cast doubt on the prospects for renewal of the African...

Novo Nordisk's Alzheimer's trial a 'lottery ticket', senior executive says

Sep 17, 2025

COPENHAGEN, Sept 17 (Reuters) - A senior Novo Nordisk executive on Wednesday described the drugmaker's ongoing trial of its blockbuster obesity medicine for treatment of Alzheimer's disease as a lottery ticket due to its uncertain prospects yet huge potential. The Danish drugmaker expects data from its pivotal Alzheimer's disease trial by the end of 2025. After blockbuster success in weight...

Oruka Therapeutics Says ORKA-001 Interim Early-Stage Data Supports Extended Dosing Intervals; Plans $180 Million Private Placement

Sep 17, 2025

06:16 AM EDT, 09/17/2025 (MT Newswires) -- Oruka Therapeutics ( ORKA ) said Wednesday that interim data from an early-stage trial of its long-acting antibody ORKA-001 showed a half-life of about 100 days, which could increase the likelihood of dosing once annually in plaque psoriasis. The company said pharmacokinetic data indicated exposures that could support higher efficacy and extended off-treatment...